A detailed history of Lord, Abbett & Co. LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 463,240 shares of TARS stock, worth $21.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
463,240
Previous 82,226 463.37%
Holding current value
$21.9 Million
Previous $2.99 Million 321.24%
% of portfolio
0.04%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Oct 07, 2024

BUY
$25.17 - $38.73 $9.59 Million - $14.8 Million
381,014 Added 463.37%
463,240 $12.6 Million
Q2 2024

Aug 14, 2024

BUY
$25.17 - $38.73 $9.59 Million - $14.8 Million
381,014 Added 463.37%
463,240 $12.6 Million
Q1 2024

Oct 07, 2024

SELL
$19.61 - $39.22 $7.47 Million - $14.9 Million
-381,014 Reduced 82.25%
82,226 $2.99 Million
Q1 2024

May 09, 2024

BUY
$19.61 - $39.22 $1.61 Million - $3.22 Million
82,226 New
82,226 $2.99 Million

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.26B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.